Cargando…

Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma

Resection is the only potential curative treatment for perihilar cholangiocarcinoma (PHC); however, complete resection is often technically challenging due to the anatomical location. Various innovative approaches and procedures were invented to circumvent this limitation but the rates of postoperat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawano, Fumihiro, Yoshioka, Ryuji, Ichida, Hirofumi, Mise, Yoshihiro, Saiura, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623956/
https://www.ncbi.nlm.nih.gov/pubmed/37927920
http://dx.doi.org/10.1002/ags3.12734
_version_ 1785130842266271744
author Kawano, Fumihiro
Yoshioka, Ryuji
Ichida, Hirofumi
Mise, Yoshihiro
Saiura, Akio
author_facet Kawano, Fumihiro
Yoshioka, Ryuji
Ichida, Hirofumi
Mise, Yoshihiro
Saiura, Akio
author_sort Kawano, Fumihiro
collection PubMed
description Resection is the only potential curative treatment for perihilar cholangiocarcinoma (PHC); however, complete resection is often technically challenging due to the anatomical location. Various innovative approaches and procedures were invented to circumvent this limitation but the rates of postoperative morbidity (20%–78%) and mortality (2%–15%) are still high. In patients diagnosed with resectable PHC, deliberate and coordinated preoperative workup and optimization of the patient and future liver remnant are crucial. Biliary drainage is recommended to relieve obstructive jaundice and optimize the clinical condition before liver resection. Biliary drainage for PHC can be performed either by endoscopic biliary drainage or percutaneous transhepatic biliary drainage. To date there is no consensus about which method is preferred. The volumetric assessment of the future remnant liver volume and optimization mainly using portal vein embolization is the gold standard in the management of the risk to develop post hepatectomy liver failure. The improvement of systemic chemotherapy has contributed to prolong the survival not only in patients with unresectable PHC but also in patients undergoing curative surgery. In this article, we review the literature and discuss the current surgical treatment of PHC.
format Online
Article
Text
id pubmed-10623956
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106239562023-11-04 Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma Kawano, Fumihiro Yoshioka, Ryuji Ichida, Hirofumi Mise, Yoshihiro Saiura, Akio Ann Gastroenterol Surg Review Articles Resection is the only potential curative treatment for perihilar cholangiocarcinoma (PHC); however, complete resection is often technically challenging due to the anatomical location. Various innovative approaches and procedures were invented to circumvent this limitation but the rates of postoperative morbidity (20%–78%) and mortality (2%–15%) are still high. In patients diagnosed with resectable PHC, deliberate and coordinated preoperative workup and optimization of the patient and future liver remnant are crucial. Biliary drainage is recommended to relieve obstructive jaundice and optimize the clinical condition before liver resection. Biliary drainage for PHC can be performed either by endoscopic biliary drainage or percutaneous transhepatic biliary drainage. To date there is no consensus about which method is preferred. The volumetric assessment of the future remnant liver volume and optimization mainly using portal vein embolization is the gold standard in the management of the risk to develop post hepatectomy liver failure. The improvement of systemic chemotherapy has contributed to prolong the survival not only in patients with unresectable PHC but also in patients undergoing curative surgery. In this article, we review the literature and discuss the current surgical treatment of PHC. John Wiley and Sons Inc. 2023-09-08 /pmc/articles/PMC10623956/ /pubmed/37927920 http://dx.doi.org/10.1002/ags3.12734 Text en © 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Kawano, Fumihiro
Yoshioka, Ryuji
Ichida, Hirofumi
Mise, Yoshihiro
Saiura, Akio
Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma
title Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma
title_full Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma
title_fullStr Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma
title_full_unstemmed Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma
title_short Essential updates 2021/2022: Update in surgical strategy for perihilar cholangiocarcinoma
title_sort essential updates 2021/2022: update in surgical strategy for perihilar cholangiocarcinoma
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623956/
https://www.ncbi.nlm.nih.gov/pubmed/37927920
http://dx.doi.org/10.1002/ags3.12734
work_keys_str_mv AT kawanofumihiro essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma
AT yoshiokaryuji essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma
AT ichidahirofumi essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma
AT miseyoshihiro essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma
AT saiuraakio essentialupdates20212022updateinsurgicalstrategyforperihilarcholangiocarcinoma